GOSS · XBRL financial data

Gossamer Bio financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (GOSS's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	—	—	0	0	115	48
General and administrative	50	46	48	38	36	38
Total operating expenses	234	216	219	184	175	219
Operating income (loss)	(234)	(216)	(219)	(184)	(60)	(171)
Interest income	—	1	2	2	2	2
Interest expense	13	19	14	14	12	11
Other income (expense)	(0)	1	2	15	14	9
Income tax expense (benefit)	—	—	0	0	1	(0)
Net income (loss)	(243)	(234)	(229)	(180)	(57)	(170)
Earnings per share, basic USD per share	(3.55)	(3.13)	(2.71)	(1.18)	(0.25)	(0.75)
Earnings per share, diluted USD per share	(3.55)	(3.13)	(2.71)	(1.18)	(0.25)	(0.75)
Weighted average shares, basic millions of shares	69	75	85	153	226	229
Weighted average shares, diluted millions of shares	69	75	85	153	226	229

Fiscal years (GOSS's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	486	183	112	32	46	38
Marketable securities	27	142	144	264	248	99
Marketable securities, non-current	—	—	—	—	—	0
Accounts receivable	—	—	—	0	5	12
Prepaid and other current assets	9	6	6	10	10	18
Total current assets	522	332	262	307	310	168
Property and equipment, net	6	5	4	2	0	0
Right-of-use asset	11	5	6	3	5	4
Total assets	539	344	272	312	315	172
Accounts payable	8	3	1	6	2	6
Accrued liabilities	21	20	21	27	15	16
Current portion of long-term debt	—	0	12	12	0	—
Total current liabilities	39	40	49	52	45	63
Long-term debt	29	29	12	1	0	—
Lease liability, non-current	8	3	3	0	4	3
Total liabilities	219	222	260	249	286	295
Accumulated deficit	(578)	(812)	(1,032)	(1,212)	(1,269)	(1,439)
Total stockholders' equity	321	121	12	63	29	(123)
Total liabilities and equity	539	344	272	312	315	172
Common shares outstanding (cover page) millions of shares	76	76	95	226	227	235

Fiscal years (GOSS's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(243)	(234)	(229)	(180)	(57)	(170)
Stock-based compensation	39	32	43	29	21	11
Depreciation and amortization	1	2	2	2	1	0
Net cash from operating activities	(176)	(189)	(187)	(159)	(3)	(171)
Purchases of property and equipment	2	2	0	0	0	0
Net cash from investing activities	215	(117)	(1)	(111)	29	156
Proceeds from issuing common stock	117	0	0	—	—	—
Repayments of long-term debt	0	0	6	12	13	0
Net cash from financing activities	313	3	117	190	(11)	6
Net change in cash	352	(303)	(71)	(80)	14	(8)

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Gossamer Bio	41	9.2	(39)*	488.8M	1.4 quarters	Q2 FY26 10-QJun 30, 2026
Tonix Pharmaceuticals Holding	176	14	(42)*	17.2M	4.2 quarters	Q2 FY26 10-QJun 30, 2026
Vanda Pharmaceuticals	62	70	(28)*	60.5M	1.7 quarters	Q3 FY26 10-QSep 30, 2026
Abeona Therapeutics	56	11	(17)*	57.2M	8.4 quarters	Q2 FY26 10-QJun 30, 2026
Ocugen	100	1.5	(12)*	339.1M	8.2 quarters	Q2 FY26 10-QJun 30, 2026
Atea Pharmaceuticals	77	not reported	(37)*	80.2M	5.9 quarters	Q2 FY26 10-QJun 30, 2026
Verastem	136	40	(44)*	90.6M	3.1 quarters	Q2 FY26 10-QJun 30, 2026
Standard Biotools	267	19	(6.2)*	394.8M	21.6 quarters	Q3 FY26 10-QSep 30, 2026
Corvus Pharmaceuticals	19	not reported	(15)*	84.1M	14.0 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.